AIMED MODELS LIMITED

What AIMED MODELS LIMITED does

AIMED MODELS LIMITED (trading as AI-Med, with a sub-brand AI-MED Innovate) is a UK-based healthcare AI startup founded in 2021. The company develops machine learning applications for medical imaging diagnostics (cancer detection across lung, brain, and breast; cardiovascular disease; retinopathy; COPD), predictive analytics for patient outcomes and readmission reduction, and process automation for clinical workflows. Its product portfolio spans a core AI-Med Platform, My IPF (IoT-based patient monitoring with NHS University Hospital of North Midlands), Virtual Clinic (remote consultations with NHS UK), Baby Check App (with the Lullaby Trust), and a PKU Management Tool for chronic condition self-management.

The company operates a hybrid commercial model: direct enterprise sales to NHS hospitals and UK healthcare institutions, supplemented by a publicly listed self-service subscription tier ($5–$50/month). The named customer roster includes five NHS trusts (University Hospital of North Midlands, Birmingham Children's Hospital, University Hospitals of Birmingham, Guys and St Thomas NHS Foundation Trust, Kings College Hospital) plus the Disability Living Foundation and Lullaby Trust. The company is privately held, headquartered in the UK, and operates exclusively in the UK/Great Britain market. Financial signals include a £500k monthly burn rate and an 18-month runway, with a stated revenue projection of £10M by 2025. The identified leadership team is small — four people including a CEO and Managing Director — and the company has no disclosed funding rounds, M&A, patents, or regulatory milestones in the source data.

Name

AIMED MODELS LIMITED

Legal name

AIMED MODELS LIMITED

Website

https://aimedmodels.com

Company type

Private

Founded year

2021

Operating status

Operating

Short description

AI-Med is a UK healthcare AI startup founded in 2021 that builds machine learning applications for medical imaging diagnostics, patient monitoring, and chronic disease management, selling primarily to NHS trusts and UK healthcare providers through subscription and enterprise deployments.

Ownership category

akta.pro rank

Product category

Healthcare AI Software

NAICS

Diagnostic Imaging Centers (621512)

SIC

Services-Health Services (8000)

akta.pro industry

PRIMARYHLACANAG

SaMD – Imaging & Signal Analysis (AI/ML)

Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

SECONDARYHDAAAEAH

Medical Imaging AI

Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Computer Vision & Video Analytics

SECONDARYHLACAPAD

Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension)

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

SECONDARYHLALAFAF

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)

Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

• Healthcare AI software
• Medical imaging diagnostics
• Patient monitoring solutions
• Predictive healthcare analytics
• Clinical decision support

Headquarters

HQ city

Coventry

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Healthcare AI Subscription: AI-Med operates on a subscription model for hospitals and healthcare providers, offering tiered pricing plans including Starter ($5/month), Professional ($25/month for 3 users), and Enterprise ($50/month for unlimited users) tiers.
2. Scalable Enterprise Solutions: Flexible, scalable AI solutions that grow with healthcare institutions, ensuring long-term success and sustainable outcomes for providers of all sizes. Revenue projected at £10M by 2025.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

AI-Med builds a subscription-based healthcare AI platform that uses machine learning to analyse medical imaging and patient data for disease detection (cancer, cardiovascular, retinopathy, COPD), predictive analytics, and personalised treatment planning. The offering includes specialised applications such as My IPF (IoT patient monitoring), Baby Check App, Virtual Clinic for remote consultations, and a PKU management tool, targeted at NHS hospitals and healthcare institutions in the UK.

Product overview

AI-Med is a unified healthcare AI platform comprising the flagship AI-Med Platform for diagnostics and patient data analysis, complemented by specialized applications including My IPF (IoT patient monitoring), Baby Check App (parental health assessment), Virtual Clinic (remote care delivery), and PKU Management Tool (chronic condition self-management). The platform's core AI capabilities span medical imaging analysis, predictive analytics, and personalized treatment recommendations, with these applications sharing a common AI infrastructure for patient data processing.

Differentiator

Problem solved

Functional benefit

Brands

• AI-MED Innovate: AI-Med's flagship healthcare AI products using machine learning to analyse patient data, improving diagnosis, treatment plans, and reducing readmission rates.

Products and services

• AI-Med Platform AI-Med's flagship healthcare AI platform that uses machine learning to analyse patient data, improving diagnosis accuracy, treatment plans, and reducing hospital readmission rates for hospitals and healthcare providers.
• AI Diagnostic Tools AI-powered diagnostic tools for early disease detection across multiple conditions including lung cancer, brain cancer, breast cancer, cardiovascular diseases, retinopathy, and COPD, used by clinicians and healthcare institutions.
• My IPF

Quantifiable outcome

• AI tools have demonstrated tangible benefits in real healthcare environments, consistently improving diagnosis accuracy, reducing hospital readmissions, and enhancing patient satisfaction
• +1 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Viz.ai: US-based AI company specializing in stroke and other acute care imaging triage with FDA clearance and broad hospital deployments. Comparable as a regulated, specialty-focused imaging AI incumbent.
• Aidoc: Israel/US-based AI imaging company with broad radiology AI suite (CT, MRI, X-ray) cleared by FDA and CE, deployed across major US health systems. Larger incumbent with deeper regulatory clearance and enterprise traction.
• Lunit: South Korea-headquartered publicly-listed medical imaging AI company with FDA-cleared and CE-marked products for chest, breast, and other cancer detection. Broader incumbent with global footprint and validated clinical evidence.
• Babylon Health: UK-headquartered digital health company offering AI-powered triage, virtual consultations, and population health tools. Comparable as a UK health-tech peer with NHS exposure and broader digital care ambitions, though larger scale and broader scope.
• DeepHealth (RadNet): US-based AI imaging subsidiary of RadNet offering breast, prostate, and chest imaging AI with FDA clearances. Larger incumbent with regulatory-cleared diagnostic AI products.

Direct peers

• Skin Analytics: UK-based AI dermatology company with CE-marked DERM tool deployed across NHS pathways. Comparable as a UK-headquartered, NHS-focused, regulatory-cleared diagnostic AI company.
• Behold.ai: UK-based AI radiology company specializing in chest X-ray and CT triage algorithms deployed with NHS trusts. Direct competitor in UK NHS medical imaging AI with regulatory-cleared products.
• Annalise.ai: Australia/UK-headquartered AI radiology platform offering comprehensive multi-disease imaging decision support across chest X-ray, CT, and other modalities. Directly comparable to AI-Med on AI medical imaging breadth and NHS market focus.
• Kheiron Medical Technologies: UK/Europe-based AI company focused on breast cancer screening (Mia) deployed with NHS breast screening programs. Direct peer in cancer imaging AI and UK NHS market.

Regional players

• Cera Care: UK-based digital home healthcare company combining IoT monitoring, predictive analytics, and in-home care delivery. Comparable to AI-Med's My IPF / Virtual Clinic chronic-care and remote-monitoring direction within the UK market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/@aimedmodels
• LinkedInlinkedin.com/company/aimedmodels

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIMED MODELS LIMITED